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Introduction: We previously reported that IL-29, a newly described member of interferon (IFN) family, was overexpressed
in blood and synovium of rheumatoid arthritis (RA) patients and triggered proinflammatory cytokine IL-6 and IL-8
mRNA expression in RA synovial fibroblasts (RA-FLS). This suggests that IL-29 has an important role in synovial inflamma-
tion. Toll-like receptors (TLRs) also activate RA-FLS to produce inflammatory mediators including tumor necrosis factor α
(TNF-α) and IL-1β in RA-FLS. Since the TLR family plays an early role in the innate immune response and the subsequent
induction of the adaptive immune response, we hypothesize that IL-29 interacts with TLRs in RA inflammation. This study
aimed to investigate the effect of IL-29 on TLR-mediated proinflammatory cytokine production in RA-FLS.
Methods: The mRNA level of IL-29 receptors (IL-28Rα and IL-10R2) in RA-FLS was determined by semi-quantitative
RT- PCR. IL-6 and IL-8 mRNA expressions in RA-FLS were evaluated by real-time PCR after pre-incubation with
IL-29 and subsequent stimulation with peptidoglycan (PGN, TLR2 ligand), or polycytidylic acid (poly(I:C), TLR3
ligand), or lipopolysaccharide (LPS, TLR4 ligand) . The production of TLR2, 3, and 4 in RA-FLS after IL-29 stimulation was
also assessed by real-time PCR and flow cytometry. IL-29 mRNA and protein expression in RA-FLS after stimulation with
PGN, poly(I:C), or LPS were measured by real-time PCR and enzyme-linked immunosorbent assay (ELISA), respectively.
Results: The IL-29 receptor complex (IL-28Rα and IL-10R2) was identified in RA-FLS. IL-29 enhanced TLR-mediated IL-6
and IL-8 expression in RA-FLS. IL-29 upregulated expression of TLR2, 3 and 4 in RA-FLS. Exposure to PGN, poly(I:C) or
LPS triggered IL-29 production by RA-FLS.
Conclusions: We show for the first time that IL-29 enhances TLR-induced proinflammatory cytokine production in
RA-FLS via upregulation of TLRs.Introduction
The classical IFN family cytokines, such as types I and II
IFNs, are known to play an important role in both
innate and adaptive immune responses during viral
infection and autoimmune inflammation. Type III IFNs,
or IFN-λs, are a newly described member of the IFN
family, including IFN-λ1 (IL-29), IFN-λ2 (IL-28A) and
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reproduction in any medium, provided the orthrough the heterodimeric receptor complex, including
the IFN-λR (IL-28Rα) chain and IL-10 receptor type 2
(IL-10R2) chain [1,2]. IL-28Rα expression is cell-specific,
whereas IL-10R2 is broadly expressed in most cell types,
such as type I IFN receptors [2]. Type III IFNs bind to
their receptors and activate the Janus kinase/signal
transducers and activators of transcription (JAK-STAT),
mitogen-activated protein kinase and Akt signaling path-
ways to induce antiviral, antiproliferative, antitumor and
immune responses [3-5]. Although the antiviral activity
has been studied extensively during the past decade, the
immunoregulatory role of type III IFNs in immune cells
is still poorly understood.
The evidence for an immunoregulatory role of IL-29 is
derived mostly from in vitro studies. For example, IL-29
inhibits the release of IL-13 in T cells [6,7]; increases theThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and induces the secretion of IL-6 and TNF from CD14+
T cells [9] as well as IL-4 and IL-13 from mast cells [10].
Investigators in a recent study reported that IL-29
induces the secretion of chemokines IFN-γ-inducible
protein 10, monokine induced by IFN-γ and IL-8 in
peripheral blood mononuclear cells (PBMCs) [11,12] in
patients with systemic lupus erythematosus (SLE), im-
plying its involvement in SLE pathogenesis. Significantly,
our recent study was the first showing that IL-29 was
highly expressed in PBMCs, serum, synovial fluid and
synovium in rheumatoid arthritis (RA) patients [13].
However, little is known about what triggers the expres-
sion of IL-29 and how elevated IL-29 levels drive syn-
ovial inflammation during RA development.
It has recently been postulated that the interaction of
genetic and environmental factors contributes to RA
pathogenesis. For instance, Toll-like receptors (TLRs)
may recognize cytomegalovirus [14,15] and Epstein-Barr
virus [16] and trigger autoimmunity in the host. TLRs
are phylogenetically conserved molecules that recognize
pathogen-associated molecular patterns and eliminate
invading pathogens by activation of immune responses.
In RA, several TLRs, including TLR2, TLR3, TLR4 and
TLR7, are highly expressed in the synovial tissues [17],
and the ligands of TLRs induce the expression of cyto-
kines (IL-1β, IL-6 and IFN-α), chemokines (IL-8) and
matrix metalloproteinases on synovial fibroblasts (FLSs)
[18-21], which contributes to RA synovial inflamma-
tion. Interestingly, proinflammatory cytokines such as
IL-1β itself further upregulate TLR expression on FLSs
[22,23], suggesting autoamplification of inflammation
in RA-FLS through interaction of TLRs and cytokines.
This notion is further supported by the evidence that
IFNs are able to modulate TLR-mediated cytokine pro-
duction in immune cells. It has been shown that IFN-α
enhances the expression of TLR3 and TLR7, leading to
increased production of IL-6 and TNF-α in RA-FLS
[24]. In addition, TLR4- and TLR8-induced p40 subunit
of IL-12 (IL-12p40) production is increased by IL-29 in
human monocyte-derived macrophage [25]. Despite this
evidence, whether IL-29 is also involved in TLR-induced
proinflammatory cytokine production in RA-FLS has
not been reported. Considering that both IL-29 and
TLRs could elevate mRNA levels of IL-6 and IL-8 in
RA-FLS, we examined the effect of IL-29 on TLR-
mediated IL-6 and IL-8 production contributing to RA
inflammation.
In the present study, we show for the first time that
TLR2, TLR3 and TLR4 engagement on RA-FLS induces
endogenous IL-29, which further enhances IL-6 and IL-8
expression by upregulation of TLR2, TLR3 and TLR4 ex-
pression. Our findings demonstrate that, in addition to
its potent antiviral activity, IL-29 plays an important rolein modulating cytokine production in RA-FLS, which
may enhance immune responses to the pathogens con-
tributing to RA inflammation.
Methods
Reagents
TRIzol reagent and SYBR Green I stain were purchased
from Invitrogen (Carlsbad, CA, USA). ExScript RT re-
agent kit and SYBR Premix Ex Taq were obtained from
TaKaRa (Dalian, China). Human IL-29 ELISA kits were
purchased from Adlitteram Diagnostic Laboratories (San
Diego, CA, USA), human IL-6 and IL-8 ELISA kits were
obtained from ExCell Biology Inc (Shanghai, China). Cell
proliferation reagent WST-1 was purchased from Roche
Diagnostics GmbH (Roche Applied Science, Mannheim,
Germany). A cell fixation permeabilization kit and Cytofix/
Cytoperm solution were purchased from BD Pharmingen
(San Jose, CA, USA), fluorescein isothiocyanate (FITC)-
conjugated anti-human TLR2 (clone TL2.1), phycoerythrin-
conjugated anti-human TLR3 (clone TLR3.7) and TLR 4
(clone HTA125) monoclonal antibody or isotope control
were obtained from eBioscience (San Diego, CA, USA).
DMEM and FBS were purchased from Gibco (Carlsbad,
CA, USA). Recombinant human IL-29 and TNF-α were
purchased from Peprotech (Rocky Hill, NJ, USA).
Polyinosinic-polycytidylic acid (poly(I:C)) and peptidoglycan
(PGN) were obtained from Invivogen (San Diego, CA,
USA). Lipopolysaccharide (LPS) was purchased from
Sigma-Aldrich (St Louis, MO, USA).
Cell culture
Human rheumatoid fibroblast-like synoviocyte MH7A
cells were isolated from intra-articular soft tissue of the
knee joints of RA patients and were established as a cell
line by transfection with the Simian virus 40 T antigen
[26]. The cell line was kindly provided by Dr David Yu
(University of California, Los Angeles, CA, USA), and
ethical approval for their use was waived by the Review
Board of the First Affiliated Hospital of Nanjing Medical
University. MH7A cells were cultured in DMEM sup-
plemented with 10% FBS, 100 U/ml penicillin and
100 μg/ml streptomycin at 37°C in a humidified at-
mosphere of 5% CO2 in air. Details regarding primary
RA fibroblast isolation and culture can be found in
Additional file 1.
Stimulation of synovial fibroblasts
To study functional upregulation of IL-29, we stimulated
MH7A cells with various concentrations of IL-29 (1, 10
and 100 ng/ml) or TNF-α (10 ng/ml) for 24 hours. After
incubation, the cell supernatants were collected for ana-
lysis of IL-6 and IL-8 production measured by ELISA as
described below.
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TLR4, we cultured MH7A cells with IL-29 (100 ng/ml)
for 24 hours and subsequently stimulated cells with the
TLR2, TLR3 and TLR4 ligand PGN (2.5 μg/ml), poly(I:C)
(25 μg/ml) or LPS (100 ng/ml), respectively. After a fur-
ther 24 hours, MH7A cells were collected for analysis of
IL-6 and IL-8 expression by real-time PCR.
To study TLR expression, we provoked MH7A cells with
various concentrations of IL-29 (1, 10 and 100 ng/ml) or
TNF-α (10 ng/ml; positive control) for 24 hours. After
incubation, MH7A cells were collected for analysis of
TLR2, TLR3 and TLR4 expression by real-time PCR
and flow cytometry assay.
To study IL-29 expression, we stimulated MH7A cells
with TLR2, TLR3 or TLR4 ligand PGN (2.5 μg/ml), poly
(I:C) (25 μg/ml) or LPS (100 ng/ml) for 24 hours, re-
spectively. After incubation, the cells were collected for
analysis of IL-29 gene expression by real-time PCR and
analysis of cell supernatants for IL-29 protein expression
by ELISA.
Viability assay by MTT
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay after
MH7A cell incubation with IL-29. Briefly, MH7A cells
(5 × 103) were incubated in a 96-well, flat-bottomed cul-
ture plate in a final volume of 200 μl/well culture
medium with or without IL-29 (100 ng/ml) for 24 hours
in a humidified atmosphere (37°C at 5% CO2). Next,
20 μl of cell proliferation reagent WST-1 were added to
each well and incubated for a further 4 hours. After incu-
bation, the plates were shaken thoroughly for 1 minute,
and the absorbance was measured at 450 nm and 630 nm
using an ELISA plate reader (BioTek, Winooski, VT, USA).
Semiquantitative RT-PCR and quantitative real-time PCR
analysis
The mRNA expression of the IL-29 complex, receptor IL-
28Rα and IL-10R2, in MH7A cells was determined by semi-
quantitative PCR. Total RNA from the cells was isolated
using TRIzol reagent. The cDNA was prepared using the
ExScript RT reagent kit according to the manufacturer’s in-
structions and then was amplified by PCR with specific




glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(5′-AGAAGGCTGGGGCTCATTTG-3′ and 5′-AGGG
GCCATCCACAGTCTTC-3′). The conditions for each
amplification were as follows: 95°C for 45 seconds,
40 cycles of denaturation at 95°C for 30 seconds, an-
nealing temperatures at 59°C for 30 seconds and extension
at 72°C for 35 seconds. The PCR products wereelectrophoresed on 2.0% agarose gels, stained with SYBR
Green I Nucleic Acid Gel Stain (Invitrogen) and visualized
by using a gel imaging system (ChemiDoc XRS + System;
Bio-Rad Laboratories, Hercules, CA, USA).
The mRNA of IL-29, IL-6, IL-8, TLR2, TLR3 and
TLR4 in MH7A cells was determined by real-time PCR.
Briefly, after synthesizing cDNA from the total RNA by
using the ExScript RT reagent kit, real-time PCR was
performed using SYBR Premix Ex Taq on a sequence de-
tection system (Eppendorf, Hamburg, Germany). Each
reaction contained 12.5 μl of 2× SYBR Green Master
Mix, 1 μl of 10 μM primers and 1 μl of cDNA to a total
volume of 20 μl. The thermal cycling conditions in-
cluded an initial denaturation step at 95°C for 30 sec-
onds, followed by 40 cycles of 5 seconds at 95°C and
30 seconds at 60°C. Primer sequences for human IL-29,
IL-6, IL-8, TLR2, TLR3, TLR4 and GAPDH are summa-
rized in Table 1. Relative gene expression was deter-
mined by the 2-ΔΔCt method.
ELISA analysis
The amounts of secreted IL-29, IL-6 and IL-8 in culture
supernatants of MH7A cells were measured by ELISA
according to the manufacturer’s instructions.
Flow cytometry analysis
After incubation with IL-29, MH7A cells were pelleted by
centrifugation at 450 g for 5 minutes, then fixed and perme-
abilized by using a cell fixation permeabilization kit. Briefly,
thoroughly resuspended cells were added to 100 μl of BD
Cytofix/Cytoperm solution and incubated for 20 minutes at
4°C. Cells were then incubated with FITC-conjugated rat
anti-human TLR2, TLR3 and TLR4 monoclonal antibody
or isotope control, respectively (at a final concentration
4 μg/ml), at 4°C for 30 minutes. After cells were washed,
they were analyzed on a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA).
Statistical analysis
Statistical analyses were performed with SPSS software
(SPSS, Inc, Chicago, IL, USA), and all figures were
drawn using GraphPad Prism 5.0 software (GraphPad
Software, La Jolla, CA, USA). Data were expressed as
means ± SD. Differences between two groups were calcu-
lated using Student’s t-test for parametric data and the
Mann–Whitney U test for nonparametric data. For all
experiments, P < 0.05 was taken as significant.
Results
Expression of IL-29 receptor in rheumatoid arthritis syn-
ovial fibroblasts
The biological functions of IL-29 depend mainly on its
receptor, thus we first examined the expression of the
IL-29 receptor complex, consisting of IL-28Rα and IL-
Table 1 Gene primers for quantitative PCR analysis
Gene name Forward (5′ to 3′) Reverse (5′ to 3′)
Human IL-29 GAAGCAGTTGCGATTTAGCC GAAGCTCGCTAGCTCCTGTG
Human IL-6 AACCTGAACCTTCCAAAGATGG TCTGGCTTGTTCCTCACTACT
Human IL-8 CATACTCCAAACCTTTCCACCCC TCAGCCCTCTTCAAAAACTTCTCCA
Human TLR2 TGTTGCAAGCAGGATCCAAAG CACAAAGTATGTGGCATTGTCCAG
Human TLR3 GGACTTTGAGGCGGGTGTT TGTTGAACTGCATGATGTAC CTTGA
Human TLR4 AGGATGATGCCAGCATGATGTC TCAGGTCCAGGTTCTTGGTTGAG
Human GAPDH AGAAGGCTGGGGCTCATTTG AGGGGCCATCCACAGTCTTC
DNA     IL-28Rα  IL-10R2  GAPDH 
Marker  
Figure 1 IL-29 receptor IL-28Rα and IL-10R2 expression in
rheumatoid arthritis synovial fibroblasts. Expression of both
receptor subunits (IL-28Rα and IL-10R2) was detected in MH7A cells
using semiquantitative RT-PCR analysis. Representative PCR products
after gel electrophoresis are shown. GAPDH, glyceraldehyde
3-phosphate dehydrogenase.
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FLS could express mRNA of both IL-28Rα and IL-
10R2 in MH7A cells (Figure 1) and primary RA-FLS
(see Additional file 2: Figure S1), implying that RA-
FLS is able to respond to IL-29 stimulation.
IL-29 induces protein expression of IL-6 and IL-8 in
rheumatoid arthritis synovial fibroblasts
We next examined whether IL-29 induces IL-6 and IL-8
release from MH7A cells, as we previously reported that
IL-29 upregulated IL-6 and IL-8 mRNA expression in
MH7A cells [13]. Consistent with this information, the
new data showed that protein levels of IL-6 and IL-8
were markedly increased in MH7A cells upon IL-29
stimulation in a dose-dependent manner (Figure 2). In
addition, using an MTT assay, we found that IL-29 en-
hanced production of IL-6 and IL-8 without affecting the
viability of MH7A cells (Figure 2C). We also observed that
IL-29 induced IL-6 and IL-8 production in the primary
culture of FLS from RA patients (see Additional file 3:
Figure S2). Together, these data confirm that IL-29 trig-
gers proinflammatory cytokine production in RA-FLS.
To further examine the kinetic changes of IL-29-
induced IL-6 and IL-8 production, we found that IL-6
and IL-8 production started to increase at 6 hours and
reached a peak at 24 hours after IL-29 treatment (see
Additional file 4: Figure S3).
IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8
expression in rheumatoid arthritis synovial fibroblasts
Because IL-29 and TLR2, TLR3 and TLR4 have all been
reported to be highly expressed in RA synovium and to
induce IL-6 and IL-8 expression in RA-FLSs, we further
investigated the potential regulatory relationship be-
tween cytokines IL-29, IL-6 and IL-8 and TLR2, TLR3
and TLR4 in RA-FLSs. MH7A cells were pretreated with
IL-29 (100 ng/ml), then further stimulated with PGN,
poly(I:C) or LPS, respectively. We found that IL-29 in-
creased IL-6 mRNA expression by approximately 1.4-,
2.0- and 2.7-fold, and IL-8 expression by 1.86-, 2.8- and
3.6-fold, after PGN, poly(I:C) or LPS stimulation, re-
spectively (Figures 3A and 3B). In addition, IL-29significantly enhanced IL-6 and IL-8 protein expression
after PGN, poly(I:C) or LPS stimulation, respectively
(Figure 3C and 3D). We further compared the difference
in protein levels of IL-6 and IL-8 in MH7A cells pre-
treated with IL-29, then stimulated them with TLR li-
gands or cells preincubated with TLR ligands and
subsequently stimulated them with IL-29. We did not
find clear differences between the two settings in the
stimulated cells (see Additional file 5: Figure S4). These
data show that TLR2, TLR3 or TLR4 stimulation leads
to production of IL-6 and IL-8, which was significantly
enhanced when the cells were primed with IL-29 com-
pared with cells stimulated with TLR ligand alone.IL-29 induces expression of Toll-like receptors 2, 3 and 4
in rheumatoid arthritis synovial fibroblasts
It has been reported that type I IFN induces TLR2,
TLR3 and TLR4 expression in RA-FLSs; therefore, we









































































Figure 2 IL-29 induces production of IL-6 and IL-8 by rheumatoid arthritis synovial fibroblasts. MH7A cells were cultured with IL-29 (1, 10
and 100 ng/ml) or TNF-α (10 ng/ml; positive control) for 24 hours, and the production of IL-6 (A) and IL-8 (B) were measured by ELISA. Because
the effects of IL-29 at 1 ng/ml on the production of IL-6 and IL-8 in MH7A cells are similar to the medium control group, the data from IL-29 at
1 ng/ml in MH7A are not shown. MH7A cells were also cultured in the presence or absence of IL-29 (100 ng/ml) for 24 hours, then cell viability
was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (C). The data present the mean ± SD for three independent
experiments. *P < 0.05 vs medium control. **P < 0.01 vs medium control.
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TLR4-mediated IL-6 and IL-8 expression in RA-FLSs
through increased TLR expression. The results showed
that TLR2, TLR3 and TLR4 mRNA were upregulated in
a dose-dependent manner and a 8.5-, 3.7- and 2.1-fold
increases in TLR2, TLR3 and TLR4 mRNA expression,
respectively, were observed in RA-FLSs after incuba-
tion with 100 ng/ml IL-29 for 24 hours (Figure 4A).
Quantitative analysis of protein levels is summarized
in Figure 4C. In line with the mRNA expression
change, TLR2, TLR3 and TLR4 protein expression was
also increased in a dose-dependent manner after IL-29
incubation. These data indicate that IL-29 enhances
TLR expression in RA-FLSs. We also found that PGN,
poly(I:C) or LPS showed a more robust capacity in in-
ducing TLR2, TLR3 or TLR4 production compared
with IL-29 treatment (100 ng/ml) (see Additional file 6:
Figure S5).
Discussion
In our previous study, we reported that IL-29 may con-
tribute to synovial inflammation during RA pathogen-
esis. In this study, we further investigated the underlying
molecular mechanism by which IL-29 contributes to RA
inflammation. We examined whether IL-29 affects cyto-
kine production in response to TLR ligands to determine
its affect on the classical pattern recognition initiated byFLS-driven responses. Our results show for the first time
that IL-29 is able to enhance TLR2, TLR3 and TLR4 ex-
pression in RA-FLS, leading to increased production of
IL-6 and IL-8. This conclusion is supported by the fol-
lowing observations: (1) IL-29 induces IL-6 and IL-8
mRNA and protein expression in RA-FLS; (2) IL-29 in-
creases mRNA and protein expression of TLR2, TLR3
and TLR4 in RA-FLS; and (3) TLR2, TLR3 and TLR4 li-
gands elevate the expression of IL-6 and IL-8 in RA-
FLS.
IL-29 has been shown to activate monocytes and mac-
rophages to produce a restricted panel of cytokines.
Jordan et al. reported that IL-29 alone, in the absence of
TLR ligands, induced high levels of IL-6 and IL-8 by hu-
man monocytes, which was further enhanced by LPS [8].
However, several other groups were unable to observe
the induction of IL-6 and IL-8 by IL-29 in the absence
of TLR ligands because no IL-29 receptor was unex-
pressed in human primary monocytes [25,27,28]. We
previously reported that MH7A cells express IL-28Rα
(the specific receptor of IL-29) evidenced by immuno-
fluorescence staining [13]. In the present study, we show
that the complex receptor of IL-29, including IL-28Rα
and IL-10R2, is expressed in both human primary RA-
FLSs and RA-FLS cell line MH7A cells. Therefore, RA-
FLSs are responsive to IL-29 and may release IL-6 and









































































































































































































Figure 3 IL-29 enhances Toll-like receptors 2-, 3- and 4-mediated IL-6 and IL-8 expression in MH7A cells. MH7A cells were pretreated
with IL-29 (100 ng/ml) for 24 hours, then further stimulated with peptidoglycan (PGN) (2.5 μg/ml), polyinosinic-polycytidylic acid (poly(I:C)) (25 μg/
ml) or lipopolysaccharide (LPS) (100 ng/ml). Expression of mRNA (A) and (B) and protein (C) and (D) of IL-6 and IL-8 was determined by real-time
PCR and ELISA, respectively. The results shown are representative of one of three independent experiments. The error bars represent mean ± SD
for triplicate wells. *P < 0.05 vs medium control. **P < 0.01 vs medium control.
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FLSs after IL-29 stimulation, which is in agreement with
the change in mRNA level of IL-6 and IL-8 after IL-29
stimulation, as we reported in our previous study. Induc-
tion of IL-6 and IL-8 (an important chemoattractant for
neutrophils) by IL-29 suggests a link between the innate
and adaptive response and early recruitment of inflam-
matory cells to the site of inflammation by IL-29.
In addition to induction of IL-6 and IL-8 production
by IL-29 in RA-FLSs, we also observed that IL-29 en-
hances TLR2, TLR3 and TLR4 mRNA and protein ex-
pression in RA-FLSs. This is important because TLR
and its ligands are abundant in RA synovium, which is
needed for the initiation of a chronic and persisting in-
flammatory response in RA. TLR2 and TLR4 elicit im-
mune responses on binding of antigens from bacteria
and endogenous ligands, leading to the production of in-
flammatory mediators. TLR3 serves as a receptor for
viral nucleic acids and have a key role in antiviral im-
munity. To the best of our knowledge, upregulation ofTLR2, TLR3 and TLR4 by IL-29 in RA-FLS has not been
previously reported.
Taken together, our data provide valid evidence that
IL-29 could trigger cytokines and TLRs expression in
FLS cell line and primary cells. Considering that we pre-
viously reported that synovial macrophages and fibro-
blasts might be the source of the high expression of
IL-29 in inflamed joint of RA, it is possible that high
levels of IL-29 derived from either synovial macrophages
or fibroblasts in turn contribute to RA pathogenesis.
In addition, the ligands of TLR2, TLR3 and TLR4 are
reported to induce IL-29 production in dendritic cells
and macrophages [29]. In line with this, our supplemen-
tary data also document that stimulation of TLR2, TLR3
and TLR4 leads to an increased production of IL-29 in
RA-FLSs for the first time (see Additional file 7: Figure
S6). Considering that macrophages produce IL-29 early
in the course of viral infection [30], it is tempting to
speculate that the induction of IL-29 is an early event
following challenge with bacterially or virally derived
Figure 4 IL-29 induces production of Toll-like receptors 2, 3 and 4 in MH7A cells. MH7A cells were stimulated with IL-29 or TNF-α (positive
control) for 24 hours, then the expression of Toll-like receptor 2 (TLR2), TLR3 and TLR4 mRNA (A) or protein (B) was measured by real-time PCR or
flow cytometry analysis, respectively. (C) Quantitative expression of TLR2, TLR3 and TLR4 protein was summarized. Because the effect of IL-29 at
1 ng/ml on the expression of the above genes in MH7A cells is similar to the medium control group, the data from IL-29 at 1 ng/ml in MH7A are
not shown in the figure. The data depicted in (A) and (B) are representative of one of three independent experiments. The error bars represent
mean ± SD for triplicate wells. The data presented in (C) are the means ± SD for three independent experiments. *P < 0.05 versus medium control.
**P < 0.01 versus medium control.
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lease IL-6, IL-8 or other proinflammatory cytokines via
TLR-mediated signaling and contributes to the chronic in-
flammation in RA. The exact mechanism underpinningthe augmented TLR response after preincubation with IL-
29 is not yet understood. On the basis of our data, we
conclude that this phenomenon results from increased ex-
pression of TLR2, TLR3 and TLR4.
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In this study, we have demonstrated the involvement of
IL-29 in an augmented TLR2, TLR3 and TLR4-mediated
inflammatory cytokine production. Our data imply an
important role of IL-29 in the activation and sustained
synovial inflammation of RA.
Additional files
Additional file 1: Primary RA fibroblasts isolation and culture.
Primary RA fibroblasts (RA-FLS) were isolated by enzymatic digestion of
synovial tissues obtained from RA patients undergoing total knee
replacement surgery. In general, synovial tissue was minced and digested
with 1% collagenase II at 37°C for 4 h. RA-FLS were cultured in DMEM
medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmos-
phere of 5% CO2 in air. This study was approved by the Ethical Commit-
tee of the First Affiliated Hospital of Nanjing Medical University, and
informed consent was obtained from all patients.
Additional file 2: Figure S1. IL-29 receptor IL-28Rα and IL-10R2 expres-
sion in primary RA-FLS. Expression of IL-29 receptor subunits IL-28Rα and
IL-10R2 in primary RA-FLS was detected by semi-quantitative RT-PCR ana-
lysis. Representative gel electrophoresis of PCR products were shown in
the figure.
Additional file 3: Figure S2. IL-29 induces protein expression of IL-6
and IL-8 in primary RA-FLS. The primary RA-FLS were cultured with IL-29
(1, 10, 100 ng/ml) or TNF-a (10 ng/ml, a positive control) for 24 h and the
production of IL-6 (A&D) and IL-8 (B& E) were measured using ELISA.
Because the effects of IL-29 at 1 ng/ml on the production of IL-6, 8 in
primary RA-FLS are similar to the medium control group, the data from
IL-29 at 1 ng/ml in primary RA-FLS are not shown in the figure. The data
present the mean ± SD for 3 independent experiments. **p < 0.01 versus
medium control.
Additional file 4: Figure S3. IL-29 induces IL-6 and IL-8 gene and
protein expression at different time points. MH7A cells were stimulated
with IL-29 (100 ng/ml) for 6 h, 12 h or 24 h, and then the expression of
IL-6 and IL-8 mRNA (A & B) or protein (C & D) was measured by real time
PCR or ELISA analysis, respectively. The data show representative of one
out three independent experiments. The error bars represent mean ± SD
for triplicate wells. *p < 0.05 versus medium control.
Additional file 5: Figure S4. IL-29 shows similar effect on TLR2, 3,
4-mediated IL-6, IL-8 production after two different treatments in MH7A
cells. MH7A cells were pretreated with IL-29 (100 ng/ml) for 24 h, and
then further stimulated with PGN (2.5 μg/ml), poly I:C (25 μg/ml) or LPS
(100 ng/ml). In contrast, MH7A cells were pretreated with PGN (2.5 μg/ml),
poly I:C (25 μg/ml) or LPS (100 ng/ml) for 24 h, and then further stimulated
with IL-29 (100 ng/ml) for 24 h. The concentration of IL-6 (A) and IL-8 (B) in
cell supernatant was examined with ELISA. The data present the mean ± SD
for 3 independent experiments. *p < 0.05 versus medium control. **p < 0.01
versus medium control.
Additional file 6: Figure S5. IL-29 induces production of TLR2, 3 and 4
in MH7A cells. MH7A cells were stimulated with IL-29 (100 ng/ml) or PGN
(2.5 μg/ml), poly I:C (25 μg/ml) or LPS (100 ng/ml) (a positive control for
TLR2, 3 and 4, respectively) for 24 h, and then the expression of TLR2, 3
and 4 mRNA (A) or protein (B) was measured by real time PCR or flow cy-
tometric analysis, respectively. (C) Quantitative expression of TLR2, 3 and
4 protein was summarized. The data depicted in (A) and (B) show repre-
sentative of one out three independent experiments. The error bars rep-
resent mean ± SD for triplicate wells. The data present in (C) show the
means ± SD for 3 independent experiments. *p < 0.05 versus medium
control. **p < 0.01 versus medium control.
Additional file 7: Figure S6. TLR ligands induce IL-29 expression in
RA-FLS. MH7A cells or primary RA-FLS were stimulated with PGN (2.5 μg/ml),
poly I:C (25 μg/ml) or LPS (100 ng/ml) alone for 24 h. The total cellular RNA
was isolated for cDNA synthesis and real time PCR was performed to deter-
mine the relative expression of IL-29 mRNA (A & C). The values werenormalized against GAPDH mRNA and relative gene expression was deter-
mined by the 2-ΔΔct method. The data show representative of one out three
independent experiments. The error bars represent mean ± SD for triplicate
wells. (B & D) Cell culture supernatants were harvested and analyzed by ELISA
kits. The data represent the mean ± SD of 3 separate experiments. *p < 0.05
versus medium control.
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